ZVRA - Zevra Therapeutics Inc
IEX Last Trade
7.65
0.260 3.399%
Share volume: 436,157
Last Updated: Fri 30 Aug 2024 09:59:57 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$7.39
0.26
3.52%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-12 | 2022-11-10 | 2023-03-07 | 2023-05-15 | 2023-08-14 | 2023-11-07 | 2024-04-01 | 2024-05-09 | |
| Assets | |||||||||
| Total Assets | 124.258 M | 119.551 M | 115.529 M | 106.595 M | 105.518 M | 138.982 M | 172.327 M | 151.283 M | |
| Current Assets | 87.435 M | 85.133 M | 93.023 M | 104.280 M | 103.427 M | 137.013 M | 86.938 M | 62.890 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 3.637 M | 2.659 M | 1.877 M | 1.174 M | 2.023 M | 43.660 M | 1.824 M | 1.868 M | |
| Short Term Investments | 3.637 M | 2.659 M | 1.877 M | 1.174 M | 2.023 M | 43.660 M | 1.824 M | 1.868 M | |
| Total Receivables | 2.820 M | 6.583 M | 8.299 M | 7.822 M | 14.033 M | 9.927 M | 17.377 M | 8.305 M | |
| Current Cash | 80.978 M | 75.891 M | 82.847 M | 95.284 M | 87.371 M | 83.426 M | 67.737 M | 52.717 M | |
| Total Non-current Assets | 36.823 M | 34.418 M | 22.506 M | 2.315 M | 2.091 M | 1.969 M | 85.389 M | 88.393 M | |
| Property Plant Equipment | 904.000 K | 852.000 K | 794.000 K | 744.000 K | 689.000 K | 642.000 K | 736.000 K | 695.000 K | |
| Other Assets | 2.384 M | 2.103 M | 1.712 M | 1.571 M | 1.402 M | 1.327 M | 10.725 M | 15.298 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 69.227 M | 67.699 M | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 4.701 M | 4.701 M | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 124.258 M | 119.551 M | 115.529 M | 106.595 M | 105.518 M | 138.982 M | 172.327 M | 151.283 M | |
| Total liabilities | 25.025 M | 25.757 M | 29.722 M | 35.191 M | 37.019 M | 71.512 M | 110.463 M | 102.465 M | |
| Total current liabilities | 7.159 M | 8.431 M | 11.726 M | 15.616 M | 18.252 M | 21.714 M | 73.720 M | 29.909 M | |
| Accounts Payable | 3.600 M | 4.279 M | 6.169 M | 10.098 M | 10.510 M | 13.080 M | 28.403 M | 22.785 M | |
| Other liabilities | 3.984 M | 3.570 M | 4.353 M | 5.925 M | 5.431 M | 5.407 M | 31.221 M | 28.853 M | |
| Current long term debt | 469.000 K | 474.000 K | 480.000 K | 470.000 K | 456.000 K | 433.000 K | 38.243 M | 583.000 K | |
| Long term debt | 13.882 M | 13.756 M | 13.643 M | 13.650 M | 13.336 M | 44.391 M | 5.522 M | 43.703 M | |
| Other liabilities | 3.984 M | 3.570 M | 4.353 M | 5.925 M | 5.431 M | 5.407 M | 31.221 M | 28.853 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 99.233 M | 93.794 M | 85.807 M | 71.404 M | 68.499 M | 67.470 M | 61.864 M | 48.818 M | |
| Common stock | 34.447 M | 34.495 M | 34.507 M | 34.467 M | 33.898 M | 34.725 M | 38.720 M | 41.779 M | |
| Retained earnings | -292.935 M | -299.551 M | -308.572 M | -320.339 M | -325.423 M | -339.468 M | -399.778 M | -416.400 M |